Gorsky M, Epstein J B
University of British Columbia, Canada.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Nov;90(5):612-7. doi: 10.1067/moe.2000.109518.
Oral Kaposi's sarcoma (KS) may represent the initial clinical manifestation of immunosuppression in human immunodeficiency virus disease. This article reviews the treatment provided to these patients and the outcome of the disease and provides the opportunity to assess the impact of improvements in the medical therapy of acquired immunodeficiency syndrome on disease outcome.
A tumor registry was examined to identify patients in whom oral KS was the first neoplastic diagnosis.
Thirty-seven cases of oral KS representing 1.9% of all cases of KS were identified as the first malignant diagnosis in patients with acquired immunodeficiency syndrome. Patients with oral KS have limited survival; the cause of death is either infection or malignancy. In our study, the palate was the most common site of primary involvement in the oral cavity. Recently diagnosed patients remained alive longer than those diagnosed earlier, and the patients with the most recently diagnosed cases were alive at the completion of the study, suggesting that medical management of human immunodeficiency virus has improved with new therapies.
口腔卡波西肉瘤（KS）可能是人类免疫缺陷病毒病免疫抑制的最初临床表现。本文回顾了为这些患者提供的治疗方法以及疾病的转归，并提供了评估获得性免疫缺陷综合征药物治疗改善对疾病转归影响的机会。
检查肿瘤登记处，以确定口腔KS为首个肿瘤诊断的患者。
37例口腔KS病例占所有KS病例的1.9%，被确定为获得性免疫缺陷综合征患者的首个恶性诊断。口腔KS患者生存期有限；死亡原因是感染或恶性肿瘤。在我们的研究中，硬腭是口腔原发性受累最常见的部位。近期诊断的患者比早期诊断的患者存活时间更长，且最新诊断病例的患者在研究结束时仍存活，这表明随着新疗法的出现，人类免疫缺陷病毒的医疗管理有所改善。
